A Phase 3, Randomized, Double Blind, Placebo And Active‑Controlled, Multicenter, Parallel‑Group Study Of The Analgesic Efficacy And Safety Of Tanezumab In Adult Subjects With Chronic Low Back Pain
Phase of Trial: Phase III
Latest Information Update: 12 Aug 2017
At a glance
- Drugs Tanezumab (Primary) ; Tramadol
- Indications Back pain
- Focus Registrational; Therapeutic Use
- Acronyms TANGO
- Sponsors Pfizer
- 07 Jul 2017 Planned primary completion date changed from 25 Oct 2017 to 17 Oct 2017.
- 13 Jun 2017 According to a Pfizer media release, results from this study are expected in 2018.
- 12 Jun 2017 Planned End Date changed from 17 Jan 2019 to 16 Jan 2019.